Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViroGates ASOCSE:VIRO +1.82%51 EV-to-FCF is -7.44 as of Aug. 29, 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 51/100 and a GF Value™ of kr7.72 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 409 Medical Devices & Instruments companies, ViroGates AS ranks worse than 244498.53% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ViroGates AS's Enterprise Value is kr90.26 Mil.
ViroGates AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr-12.14 Mil. Therefore, ViroGates AS's EV-to-FCF for today is -7.44.
The historical rank and industry rank for ViroGates AS's EV-to-FCF or its related term are showing as below:
OCSE:VIRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -49.54 Med: -8.21 Max: -2.32
Current: -7.44
During the past 10 years, the highest EV-to-FCF of ViroGates AS was -2.32. The lowest was -49.54. And the median was -8.21.
OCSE:VIRO's EV-to-FCF is ranked worse than 100% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 24.74
vs OCSE:VIRO: -7.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ViroGates AS's PE Ratio (TTM) for today is calculated as:
ViroGates AS's share price for today is kr11.20.
ViroGates AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.856.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ViroGates AS EV-to-FCF Related Terms
ViroGates AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ViroGates AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ViroGates AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ViroGates AS's EV-to-FCF falls into.
ViroGates AS's current Enterprise Value is kr90.26 Mil.
ViroGates AS's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-12.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (OCSE:VIRO) has a EV-to-FCF of -7.44 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #999999 out of 409 companies in the Medical Devices & Instruments industry.
Is ViroGates AS's EV-to-FCF too high?
ViroGates AS's current EV-to-FCF is -7.44. Based on the distribution chart, ViroGates AS ranks #999999 out of 409 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #999999 out of 409 companies for EV-to-FCF. This places ViroGates AS in the lower half of its industry. The industry median EV-to-FCF is 24.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.74, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current EV-to-FCF is -7.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr7.72, compared to a current price of kr11.20 — trading 45.1% above its estimated fair value. The current EV-to-FCF is -7.44. ViroGates AS's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current EV-to-FCF is -7.44 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr11.20 is trading 45.1% above its estimated GF Value™ of kr7.72.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
EV-to-FCF: -7.44
GF Value™: kr7.72 vs. price of kr11.20 (45.1% above fair value)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
51GF Score
Get the complete analysis for OCSE:VIRO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
